brilinta ticagrelor tablet 90mg per tablet 14tablets per carton

Description

Indication & Scope

BRILINTA® is a prescription oral P2Y12 receptor antagonist indicated, in combination with low-dose aspirin, to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It is also indicated to reduce the risk of stent thrombosis in patients undergoing percutaneous coronary intervention (PCI).

Mechanism: Ticagrelor is a reversible P2Y12 receptor antagonist that inhibits ADP-mediated platelet activation and aggregation, reducing thrombus formation.
Drug class: Oral P2Y12 receptor antagonist (antiplatelet agent).
Clinical use: Treatment of acute coronary syndrome, secondary prevention after myocardial infarction, and prevention of thrombotic events following PCI.

Specification

Generic Name	Ticagrelor Tablets
Brand Name	BRILINTA®
Ingredient	Ticagrelor
Dosage Form	Tablet
Package	90 mg/tablet, 14 tablets/carton
Conditions Treated	Acute coronary syndrome, myocardial infarction, coronary artery disease requiring antiplatelet therapy
Taboos	Hypersensitivity to ticagrelor; active pathological bleeding; history of intracranial hemorrhage; severe hepatic impairment
Place of origin	Sweden
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store below 30°C in a dry place, protected from light.
Manufacturer	AstraZeneca AB
Registration Authority	National Medical Products Administration (NMPA), China
Approval Number	HJ20171079
Approval Date	June 25, 2026
Shelf Life	24 months

How to use ?

Recommended Dose: The recommended loading dose is 180 mg once, followed by 90 mg twice daily. BRILINTA® should be administered together with low-dose aspirin (75–100 mg daily) unless otherwise directed.

Time: Take twice daily, with or without food, at approximately the same times each day.

Instructions for use: Swallow tablets whole with water. Continue treatment for up to 12 months after ACS, or as recommended by the physician. Do not discontinue therapy without medical advice because premature discontinuation increases thrombotic risk.

Interaction: Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) or strong CYP3A4 inducers (e.g., rifampin). Use caution with anticoagulants, NSAIDs, and other antiplatelet agents due to increased bleeding risk.

Side effects: Common adverse reactions include bleeding, dyspnea, bruising, epistaxis, headache, dizziness, nausea, and diarrhea. Serious bleeding, including intracranial hemorrhage, may rarely occur.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

What is BRILINTA® used for?

It is used with low-dose aspirin to reduce the risk of heart attack, stroke, cardiovascular death, and stent thrombosis in patients with acute coronary syndrome or a history of myocardial infarction.

How should BRILINTA® be taken?

The usual maintenance dose is 90 mg twice daily, following a 180 mg loading dose, together with 75–100 mg of aspirin daily.

Can BRILINTA® be taken without aspirin?

For most approved indications, BRILINTA® should be used in combination with low-dose aspirin, unless otherwise instructed by a physician.

What are the common side effects?

The most common side effects include bleeding, shortness of breath (dyspnea), bruising, nosebleeds, headache, and nausea.